|Articles|February 4, 2010
Podcast - Quality by Design: Where We Stand Now
Advertisement
Quality by Design: Where We Stand Now
On what aspects of Quality by Design is there now consensus within the industry and regulatory bodies, and what remains to be sorted out?
Join Laura Bush, Editor in Chief of BioPharm International and John Towns, Senior Director of Global CMC Regulatory Affairs at Eli Lilly, as they discuss the current state of QbD.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
New Cord Blood Stem Cell Approval Alters Biopharma Manufacturing Priorities
2
How Mitigation and Maintenance Protect Against Future Risk
3
FDA Decision Accelerates Rare Disease Gene Therapy Regulatory Pathways
4
GSK and Oxford BioTherapeutics Drive Antibody-Based Cancer Drug Discovery at Industry Scale
5
